Data as of Nov 4, 2026.

vsOpen in the appCompare their flowsaskIQ about these two fundsAsk the committee about these two funds
Thematic ETFs

BBP vs IDNA: Holdings Overlap & Returns

Share
Share on XDownload as PDF

Over the year to Nov 4, 2026, BBP returned +44.4% to IDNA's +81.1%; 17% of their weight is in the same names.

askIQ about this page

askIQ about BBP and IDNA

Net assets: $99m on Jul 31, 2026 for Virtus Biotech ETF, and $340m on Nov 3, 2026 for iShares Genomics Immunology and Healthcare ETF.

At a glance
10.5%
BBP in the S&P 500
27.4%
IDNA in the S&P 500
+44.4%
BBP total return, 1 year
+81.1%
IDNA total return, 1 year
BBP · 1 year to Nov 4, 2026 90% of its weight is outside the S&P 500
90% of its weight is outside the S&P 50011% of BBP's weight is in S&P 500 companies and 90% is outside the index. Holdings as of Jul 31, 2026.11%90%inof its weight outside the S&P 500active share 99% · top ten 20% of the fund · 67 holdings as filed for Jul 31, 2026 · Nasdaq-100: 7% in90% of its weight is outside the S&P 50011% of BBP's weight is in S&P 500 companies and 90% is outside the index. Holdings as of Jul 31, 2026.11%90%inof its weight outside the S&P 500active share 99% · Nasdaq-100: 7% in

11% of BBP's weight is in S&P 500 companies and 90% is outside the index. Holdings as of Jul 31, 2026.

IDNA · 1 year to Nov 4, 2026 73% of its weight is outside the S&P 500
73% of its weight is outside the S&P 50027% of IDNA's weight is in S&P 500 companies and 73% is outside the index. Holdings as of Nov 3, 2026.27%73%in the S&P 500of its weight outside the S&P 500active share 99% · top ten 51% of the fund · 52 holdings as published by its issuer for Nov 3, 2026 · Nasdaq-100: 8% in73% of its weight is outside the S&P 50027% of IDNA's weight is in S&P 500 companies and 73% is outside the index. Holdings as of Nov 3, 2026.27%73%inoutside the S&P 500active share 99% · Nasdaq-100: 8% in

27% of IDNA's weight is in S&P 500 companies and 73% is outside the index. Holdings as of Nov 3, 2026.

Pair scorecard

BBP costs 0.13 points a year less; their one-year returns differ by 36.7 points.

BBP vs IDNA: Holdings Overlap & Returns
MeasureBBPIDNA
Return
Total return, 1 year+44.4%+81.1%
Drawdown
Below its all-time high16.5%, high on Sep 2, 2021
Benchmark
What it tracksBiotechGenomics and gene editing
Cost and size
Expense ratio0.34%0.47%
Net assets, BBP as of Jul 31, 2026 and IDNA as of Nov 3, 2026$99m$340m
Holdings
Holdings in common17%

Method

What they share

17%

By the books each fund has filed, BBP and IDNA hold 17% of their money in the same securities at the same weight. Holdings dated Jul 31, 2026 and Nov 3, 2026.

0 half 100%

half

17% in common

Positions both hold · largest shared weight first BBP IDNA
REGENERON PHARMACEUTICALS 1.72% 4.24%
INCYTE CORP 1.52% 3.18%
MODERNA INC 1.51% 13.33%
VERTEX PHARMACEUTICALS INC 1.48% 3.29%
IMMUNITYBIO INC 1.39% 2.71%
BIONTECH SE 1.38% 2.73%
EXELIXIS INC 1.38% 3.80%
IOVANCE BIOTHERAPEUTICS INC 1.37% 2.98%
CRISPR THERAPEUTICS AG 1.33% 1.24%
NOVAVAX INC 1.14% 1.32%
NUVATION BIO INC 1.77% 1.01%
RIGEL PHARMACEUTICALS INC 1.54% 0.76%
Only in one fund ↓
Only in BBP
CRINETICS PHARMACEUTICALS INC 3.34%
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC 1.97%
PRECIGEN INC 1.94%
OMEROS CORP 1.87%
PROTAGONIST THERAPEUTICS INC 1.71%
ACADIA PHARMACEUTICALS INC 1.69%
BRIDGEBIO PHARMA INC 1.65%
BEONE MEDICINES LTD 1.65%
Only in IDNA
GENMAB 6.26%
TWIST BIOSCIENCE 5.61%
BAYER AG 3.85%
TAKEDA PHARMACEUTICAL 3.77%
REVOLUTION MEDICINES 3.60%
CARIS LIFE SCIENCES 3.50%
MERCK & CO INC 3.32%
ROCHE PS PAR AG 3.20%
Check overlap with more funds →

Window by window

Window by window: BBP vs IDNA: Holdings Overlap & Returns
Total return
WindowBBPIDNA
3 months+8.8%+32.4%
6 months+16.6%+45.6%
1 year+44.4%+81.1%
3 years+113.7%+134.8%
Since launchNot the same days: BBP Dec 2014 · IDNA Jun 2019+310.5%+88.1%

Open this comparison in the app →

Side by side

BBP Virtus Biotech ETF · Holds 67 stocks in biotech, 10% of its weight in S&P 500 companies IDNA iShares Genomics Immunology and Healthcare ETF · Holds 52 stocks in genomics and gene editing, 27% of its weight in S&P 500 companies
Theme Biotech Genomics and gene editing
In the S&P 500 10.5% 27.4%
Active share vs the S&P 500 99.0% 99.1%
In the Nasdaq-100 7.1% 7.5%
Holdings 67 52
Top ten, share of the fund 19.6% 51.3%
Expense ratio 0.34% 0.47%
Fee for the differing part 0.34% 0.47%
Total return, 1 year +44.4% +81.1%
vs its benchmark not measured not measured
Below its high −4.1% −16.5%
Net assets, BBP as of Jul 31, 2026 and IDNA as of Nov 3, 2026 $99m $340m

As of Nov 4, 2026. Source: ETFIQ.

17% of the two portfolios are the same securities at the same weight.

Alert

IDNA flows, by email on Sundays.

One-click unsubscribe. See Privacy.

About each fund
BBP

By weight, 10% of BBP's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 20% of the fund across 67 positions, as filed for Jul 31, 2026. Over the year to Nov 4, 2026 the fund returned +44.4% with distributions reinvested.

IDNA

By weight, 27% of IDNA's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 51% of the fund across 52 positions, as published by its issuer for Nov 3, 2026. Over the year to Nov 4, 2026 the fund returned +81.1% with distributions reinvested. It sits 16.5% below its all-time high of Sep 2, 2021.

Questions people ask

Do BBP and IDNA hold the same stocks?
By their latest filings, 17% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.
Which is more different from the S&P 500, BBP or IDNA?
BBP has 10% of its weight in S&P 500 names and IDNA has 27%, so IDNA differs more from the index.
Which is cheaper, BBP or IDNA?
BBP charges 0.34% a year and IDNA charges 0.47%, so BBP is cheaper. Fees come from each fund's prospectus.
Other comparisons
Cite this pageCitation, APA and Markdown

ETFIQ, BBP against IDNA, data as of Nov 4, 2026. https://etfiq.com/compare/themes/bbp-vs-idna

Open data →

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.